Skip to main content
TipRanks
Go Ultimate75% OFF

Biofrontera (0DOL) AI Stock Analysis

0 Followers
GB:0DOL

Biofrontera

(LSE:0DOL)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong Gross MarginAn approximately 83% gross margin indicates that Biofrontera’s products retain substantial value after direct production costs. If revenue stabilizes, this gross-profit profile can provide meaningful operating leverage and support investment in commercial execution or product development.
Negative Factors
Persistent Cash BurnNegative operating and free cash flow show that the core business is consuming cash rather than funding itself. Because negative cash generation also occurred across 2022–2024, Biofrontera may face sustained funding pressure unless revenue scales or costs decline materially.

Biofrontera (0DOL) vs. iShares MSCI United Kingdom ETF (EWC)

-100%-75%-50%-25%0%25%50%GB:0DOL-80.56%EWC+15.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 123.91M
Dividend Yield
―
Average Volume (3M)
263
Price to Earnings (P/E)
-1.5
Beta (1Y)
-0.50
Revenue Growth
―
EPS Growth
―
Country
UK
Employees
62
Sector
Healthcare
Sector Strength
51
Industry
Medical - Pharmaceuticals

Biofrontera Business Overview & Revenue Model

Company Description

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps...

Biofrontera Earnings Call Summary

Earnings Call Date:Jun 03, 2026(Q1-2026)|% Change Since:15.83%|Next Earnings Date:May 29, 2019
Earnings Call SentimentPositive

The call presented meaningful operational and clinical progress: double-digit revenue growth (17% YoY), a substantial gross margin expansion to ~80% following the strategic transaction, near-breakeven operating cash usage ($70k), strong clinical/regulatory milestones (sNDA accepted with PDUFA date, positive Phase III AK data, encouraging acne Phase II), and regained NASDAQ compliance. Offsetting these positives are persistent GAAP losses (net loss $4.8M), higher SG&A (up ~27%), patent/legal and manufacturing transition costs, modest cash reserves ($6.3M) with a going concern qualification, and exposure to tariff/supply risks. Overall, the highlights—particularly the margin improvement, cash-flow progress, and clinical/regulatory advances—meaningfully outweigh the lowlights, though execution and financing risks remain.

Positive Updates

Revenue Growth
Product revenues of $10.1M in Q1 2026, up ~17% versus $8.6M in Q1 2025, driven by ~16% Ameluz unit volume growth and a price increase implemented in Q4 2025 (price increase contributed ~ $0.2M).

Negative Updates

Net Loss and GAAP Earnings Pressure
Net loss widened to $4.8M (loss per share $0.41) in Q1 2026 versus $4.2M (loss per share $0.47) in Q1 2025, reflecting nonrecurring items and a $0.8M swing in fair value of warrant liabilities that adversely impacted GAAP results.

Company Guidance

Management guided a 2026 path to cash‑flow breakeven supported by Q1 results: product revenues $10.1M (+17% YoY from $8.6M), Ameluz volumes ~29,000 tubes (+16% from ~25,000), a Q1 price lift that added ~$0.2M, 32 RhodoLED lamps shipped (installed base ~773 lamps in 709 offices), and a gross margin of ~80% (vs ~62% YoY) driven by a ~40% decline in cost of goods ($3.1M to $1.8M) and a $1.2M earnout (earnout terms: 12% of net sales ≤ $65M, 15% > $65M); financials also showed adjusted EBITDA of -$3.6M (margin -35% vs -51%), operating loss $4.3M, net loss $4.8M ($0.41/sh), cash used in operations ~$70k (vs $4.1M), cash $6.3M (vs $6.4M), a $3.4M AR collection, expectation to file an sNDA for AK in Q3, a sBCC PDUFA on Sept 28, 2026, and a long‑term gross margin target of 80–85% (patent protection through 2043).

Biofrontera Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0DOL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DE:EUZDE:EUZ80OutperformEUR 930.47M17.2220.26%1.47%4.05%36.66%
DE:MRKDE:MRK63NeutralEUR 65.54B33.826.40%1.47%0.81%-35.12%
DE:DMPDE:DMP54NeutralEUR 1.69B13.5620.60%2.58%1.71%15.95%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
DE:EVTDE:EVT42NeutralEUR 484.66M-2.68-25.63%―-5.03%-13.63%
DE:HPHADE:HPHA41NeutralEUR 96.38M-3.22200.64%―206.78%-13.94%

* Healthcare Sector Average

Performance Comparison

-50%0%GB:0DOLDE:EUZDE:EVTDE:MRKDE:HPHADE:DMPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0DOL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0DOLBiofrontera AG2.78-11.52-80.56%
DE:EUZEckert & Ziegler Strahlen und Medizintechnik14.98-0.27-1.78%
DE:EVTEvotec AG (UK)2.73-2.48-47.60%
DE:MRKMerck KGaA149.5039.4135.80%
DE:HPHAHeidelberg Pharma AG2.06-0.91-30.64%
DE:DMPDermapharm Holding34.05-0.40-1.16%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.